References
- Connors M, Graham BS, Lane HC, Fauci AS. SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn. Ann Intern Med 2021;174(5) :687-90. https://doi.org/10.7326/M21-0111
- World Health Organization. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 VaxzevriaTM, SII COVISHIELDTM). Accessed August 6, 2021, https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1
- Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet 2021;397(10269):99-111. https://doi.org/10.1016/S0140-6736(20)32661-1
- Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet 2021;397(10277):881-91. https://doi.org/10.1016/S0140-6736(21)00432-3
- Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet 2020;396(10249): 467-78. https://doi.org/10.1016/S0140-6736(20)31604-4
- World Health Organization. Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine. Accessed August 6, 2021, https://www.who.int/news/item/07-04-2021-interim-statement-of-the-covid-19-subcommittee-of-the-who-global-advisory-committee-on-vaccine-safety
- Peltier E. Denmark says it's permanently stopping use of the AstraZeneca vaccine. The New York Times. Updated April 14, 2021. Accessed August 6, 2021, https://www.nytimes.com/2021/04/14/world/europe/denmark-astrazeneca-vaccine.html
- World Health Organization. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barre Syndrome (GBS) following adenovirus vector COVID-19 vaccines. Accessed August 6, 2021, https://www.who.int/news/item/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs
- Ang L, Lee HW, Choi JY, Zhang J, Lee MS. Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines. Integrative Medicine Research 2020;9(2):100407. https://doi.org/10.1016/j.imr.2020.100407
- Korea Disease Control and Prevention Agency. Adverse Event Management Guidelines after Coronavirus Disease 19 Vaccination (1-3rd Edition). Accessed August 6, 2021 https://ncv.kdca.go.kr/board.es?mid=a12101000000&bid=0031#content
- Ministry of Food and Drug Safety. Guidelines for evaluating severity of adverse reactions in vaccine clinical trials. Accessed August 6, 2021, https://www.mfds.go.kr/brd/m_1060/view.do?seq=13009&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=83
- US Food and Drug Administration. Guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Accessed August 6, 2021, https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical
- World Health Organization (WHO)-Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. Accessed August 6, 2021, https://www.who.int/publications/m/item/WHO-causality-assessment
- European Medicines Agency. Assessment report COVID-19 vaccine AstraZeneca. Accessed August 6, 2021, https://www.ema.europa.eu/en/documents/assessment-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf
- World Health Organization. Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca. Accessed August 6, 2021, https://www.who.int/publications/i/item/background-document-on-the-azd1222-vaccine-against-covid-19-developed-by-oxford-university-and-astrazeneca
- Bae S, Lee YW, Lim SY, Lee JH, Lim JS, Lee S, et al. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea. Journal of Korean Medical Science 2021;36(17):e115. https://doi.org/10.3346/jkms.2021.36.e115
- Nam Dj, Oh MS. Review about the Study of Ssanghwa-tang Published in Korea from 2000 to 2019. Journal of Haehwa Medicine 2019; 28(2):12-9.
- Andrade RJ, Aithal GP, Bjorns on ES, Kaplowitz N, Kullak-Ublick GA, Larrey D, et al. EASL Clinical Practice Guidelines: Drug-induced liver injury. Journal of Hepatology 2019;70(6):1222-61. https://doi.org/10.1016/j.jhep.2019.02.014
- Wang D, Liu Y, Zhao W. The Adjuvant Effects on Vaccine and the Immunomodulatory Mechanisms of Polysaccharides From Traditional Chinese Medicine. Frontiers in Molecular Biosciences 2021;8:655570. https://doi.org/10.3389/fmolb.2021.655570
- Huang J, Tao G, Liu J, Cai J, Huang Z, Chen JX. Current Prevention of COVID-19: Natural Products and Herbal Medicine. Front Pharmacol 2020;11:588508. https://doi.org/10.3389/fphar.2020.588508
- Taguchi A, Kawana K, Yokoyama T, Adachi K, Yamashita A, Tomio K, et al. Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner. Vaccine 2012;30(36):5368-72. https://doi.org/10.1016/j.vaccine.2012.06.027
- European Medicines Agency. Vaxzevria (previously COVID-19 Vaccine AstraZeneca) : EPAR - Public assessment report. Updated February 18, 2021. Accessed August 6, 2021, https://www.ema.europa.eu/en/documents/assessment-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf